vorsetuzumab mafodotin vorsetuzumab mafodotin vorsetuzumab mafodotin (sgn-75) is an antibody-drug conjugate (adc) directed to the protein cd70 designed for the treatment of cancer. it is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin f (mmaf), a cytotoxic agent. vorsetuzumab mafodotinmonoclonal antibodytype?sourcehumanized (from mouse)targetcd70clinical dataother namessgn-75atc codenonelegal statuslegal status discontinued identifierscas number1165741-01-4 ychemspidernoneunii699619yvtqkeggd10341chemical and physical dataformulac6476h10006n1726o2028s50(c49h78n6o11)3-5molar mass150 kg/mol this drug was developed by seattle genetics, inc. the drug completed phase i clinical trials for renal cell carcinoma, but development was discontinued in 2013. no reason was given but sg plan to start clinical trials of sgn-cd70a in 2014.